$1.85
3.14% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Innate Pharma - ADR Stock price

$1.85
-0.31 14.35% 1M
-0.26 12.36% 6M
+0.01 0.54% YTD
-0.14 7.04% 1Y
-0.89 32.48% 3Y
-4.52 70.94% 5Y
-4.20 69.42% 10Y
-4.20 69.42% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.06 3.14%
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Key metrics

Basic
Market capitalization
$167.0m
Enterprise Value
$165.6m
Net debt
$-1.4m
Cash
$94.7m
Shares outstanding
83.8m
Valuation (TTM | estimate)
P/E
negative | 17.76
P/S
11.29 | 2.29
EV/Sales
11.20 | 2.27
EV/FCF
negative
P/B
14.98
Financial Health
Equity Ratio
7.95%
Return on Equity
-560.01%
ROCE
-66.06%
ROIC
-383.32%
Debt/Equity
9.01
Financials (TTM | estimate)
Revenue
$14.8m | $73.1m
EBITDA
$-58.1m | $11.8m
EBIT
$-60.4m
Net Income
$-58.0m | $8.7m
Free Cash Flow
$-8.5m
Growth (TTM | estimate)
Revenue
-75.69% | 394.03%
EBITDA
-554.39% | 120.34%
EBIT
-307.10%
Net Income
-553.66% | 115.06%
Free Cash Flow
79.13%
Margin (TTM | estimate)
Gross
-
EBITDA
-392.81% | 16.18%
EBIT
-408.61%
Net
-391.94% | 11.95%
Free Cash Flow
-57.73%
More
EPS
$-0.71
FCF per Share
$-0.10
Short interest
0.06%
Employees
181.00
Rev per Employee
$80.00k
Show more

Is Innate Pharma - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Innate Pharma - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Innate Pharma - ADR forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Innate Pharma - ADR forecast:

Buy
73%
Hold
27%

Financial data from Innate Pharma - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
15 15
76% 76%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
14% 14%
150%
- Research and Development Expense 58 58
0% 0%
393%
-58 -58
554% 554%
-393%
- Depreciation and Amortization 2.34 2.34
61% 61%
16%
EBIT (Operating Income) EBIT -60 -60
307% 307%
-409%
Net Profit -58 -58
554% 554%
-392%

In millions USD.

Don't miss a Thing! We will send you all news about Innate Pharma - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innate Pharma - ADR Stock News

Neutral
Business Wire
11 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences.
Neutral
Business Wire
15 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the Europ...
Neutral
Business Wire
about one month ago
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.
More Innate Pharma - ADR News

Company Profile

Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Head office France
CEO Jonathan Dickinson
Employees 181
Founded 1999
Website www.innate-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today